Related Experiment Video

Updated: Mar 25, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

MicroRNAs in heart failure: from biomarker to target for therapy

Eline L Vegter1, Peter van der Meer1, Leon J de Windt2

  • 1Department of Cardiology, University Medical Centre Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands.

European Journal of Heart Failure
|February 13, 2016
PubMed

Insights

MicroRNAs (miRNAs) are key in heart failure, impacting cardiac fibrosis and hypertrophy. This review explores their potential as circulating biomarkers and therapeutic targets for heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Biomarker Discovery

Background:

  • MicroRNAs (miRNAs) are small, non-coding RNAs implicated in cardiovascular diseases.
  • They regulate key pathophysiological processes in heart failure, including cardiac fibrosis and hypertrophy.
  • miRNAs are found in both cardiac tissue and circulation.

Purpose of the Study:

  • To review the role of miRNAs in heart failure pathogenesis.
  • To explore the potential of miRNAs as circulating biomarkers for diagnosis and prognosis.
  • To discuss miRNAs as therapeutic targets for heart failure treatment.

Main Methods:

  • Literature review of current research on miRNAs in heart failure.
  • Analysis of studies investigating miRNA expression in heart failure patients.
  • Examination of preclinical and clinical studies on miRNA-based therapies.

Main Results:

  • miRNAs are integral to heart failure pathophysiology, influencing fibrosis and hypertrophy.
  • Circulating miRNAs show promise as diagnostic and prognostic biomarkers.
  • miRNA mimics and antimirs are emerging therapeutic strategies.

Conclusions:

  • miRNAs represent a significant area of research in heart failure.
  • Further investigation is needed to elucidate the function of circulating miRNAs.
  • miRNAs hold considerable potential for both biomarker and therapeutic applications in heart failure management.
Keywords:
AntimirCirculationHeart failureMicroRNAs

More Related Videos

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization08:22

Tissue-specific miRNA Expression Profiling in Mouse Heart Sections Using In Situ Hybridization

Published on: September 15, 2018

8.7K
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
737
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.1K